The CCK8 assay revealed that the impact of CCT3 knockdown on Sorafenib sensitivity in HCC cells was no longer observed upon simultaneous knockdown of ACTN4 or TFRC (Figs. 5H, S5J). This evidence concerns the gene TFRC and hepatocellular carcinoma.